|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
1/18/2011 7:19:29 AM
Smiths Group confirms that it has received an approach for Smiths Medical which it has rejected.
The value offered was £2.45 billion in cash, as a best and final offer, subject inter alia, to extensive due diligence and completion of financing.
The Board has carefully considered this approach with its advisers and has concluded that it would not be in the interests of shareholders to pursue discussions on the basis of an indication at this price level.
In reaching this conclusion, the Board has taken into account the quality and highly cash generative nature of Smiths Medical, both standalone and in the context of the Group as a whole.
Smiths Group www.smiths.com is a world leader in the practical application of advanced technologies. It comprises five divisions - Smiths Detection, John Crane, Smiths Medical, Smiths Interconnect and Flex Tek - that supply products and services for markets in threat and contraband detection, energy, medical devices, communications and engineered components. Smiths Group employs around 23,000 people in more than 50 countries.
|
|
|
|
|
|
|
|
|
|
|